Updates | Pfizer

Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B

Read more about Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B

If approved in Europe, marstacimab is expected to become the first once-weekly subcutaneous treatment for people living with severe hemophilia B and the first to be administered via a pre-filled pen for people living with severe hemophilia A or B

NEW YORK, September 20, 2024 – Pfizer Inc.

Pfizer Wraps Up 8th Year of Immersive Girls Who Code Program

Read more about Pfizer Wraps Up 8th Year of Immersive Girls Who Code Program

From July 29th to August 9th, Pfizer hosted its 8th Summer Immersion Program in partnership with Girls Who Code (GWC). Throughout the event, more than 60 students participated in colleague-led learning sessions on professional development, data science, cybersecurity, and more.

August Social Media Round-Up—the Summer Games, Girls Who Code, and More

Read more about August Social Media Round-Up—the Summer Games, Girls Who Code, and More

Pfizer closed out the summer months with a splash. Check out our monthly round up for more!

PfizerForAll Strives to Simplify How You Access Healthcare

Read more about PfizerForAll Strives to Simplify How You Access Healthcare

It’s not breaking news to say that healthcare in the U.S. is complicated.

The ABCs (and WYs) of Meningococcal Meningitis

Read more about The ABCs (and WYs) of Meningococcal Meningitis

As you prepare your kids for a new year, it’s important to help protect their health from the myriad germs and viruses that spread throughout fall and winter.

Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price

Read more about Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price

NEW YORK, August 15, 2024 — Pfizer Inc. (NYSE: PFE) today announced that on August 15, 2024, the U.S. Department of Health and Human Services released the “maximum fair price” (MFP) for ELIQUIS® (apixaban), which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA). The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00.

Living Our Values Through Pfizer’s Refugee Initiatives

Read more about Living Our Values Through Pfizer’s Refugee Initiatives

Pfizer's commitment to supporting refugees is a cornerstone of our corporate responsibility.

Pfizer Sponsors Essence Festival for Third Consecutive Year

Read more about Pfizer Sponsors Essence Festival for Third Consecutive Year

Last month, over the long 4th of July holiday weekend, Pfizer attended and sponsored the Essence Festival of Culture, the largest festival in the U.S., attracting over 500,000 attendees to New Orleans, for the third consecutive year.

July Social Media Round-Up—Summer Interns, 175 Days of Good, and More

Read more about July Social Media Round-Up—Summer Interns, 175 Days of Good, and More

Pfizer jumped into the summer holidays with another eventful month. See what our leadership has been up to then catch up on our corporate social accounts where we shine a spotlight on Pfizer partners, colleagues, and communities.

Uninhibited: Fostering Conversation Within the IBD Community

Read more about Uninhibited: Fostering Conversation Within the IBD Community

The spirit of Uninhibited was evident throughout Pfizer’s inaugural Global IBD Community Summit in June, a unique event gathering stakeholders from around the globe in Warsaw, Poland.

Subscribe to Updates